Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1437.593
- +15.418+1.08%
Close Dec 6 16:00 ET
1447.804High1420.327Low
1424.123Open1422.175Pre Close26.84MVolume10Rise70.30P/E (Static)951.71MTurnover--Flatline1.87%Turnover Ratio172.32BMarket Cap--Fall169.97BFloat Cap
Constituent Stocks: 10Top Rising: EDIT+12.04%
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Positive
94.7% of evaluable patients achieved complete resolution of severe VOEs
86.8% of evaluable patients achieved complete resolution of VOEs
100% success rate in pediatric patients (10/10) for VOE resolution
No stroke recurrence in patients with prior history through 9 y...
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditionin...
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Sunday, 8th December at 12:30 pm
Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
$Roth CH Acquisition V Co (ROCL.US)$ Ticker change tomorr...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Saturday, 7th December at 12:00 pm
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up
bluebird...
No comment yet